Lorlatinib is currently the most advanced, potent and selective anaplastic lymphoma kinase
(ALK) tyrosine kinase inhibitor for the treatment of ALK-positive non-small cell lung cancer in …

Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase
inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated …

The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy
with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor …

The identification of anaplastic lymphoma kinase (ALK), an oncogenetic driver mutation, in
lung cancer has paved the way for a new era in the treatment of non-small cell lung cancer …

PURPOSE Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma
kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced …

Targeted therapy changed the standard of care in ALK-dependent tumors. However,
resistance remains a major challenge. Lorlatinib is a third-generation ALK inhibitor that …

Since 2011, with the approval of crizotinib and subsequent approval of four additional
targeted therapies, anaplastic lymphoma kinase (ALK) inhibitors have become important …

Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete
responses in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC) …

In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer,
resistance to crizotinib developed because of a mutation in the ALK kinase domain. This …

Objectives To analyze the efficacy and safety of lorlatinib in Asian and non-Asian patients
with pretreated anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung …